Treatment decisions for localized prostate cancer
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
OBJECTIVE: To identify what factors men consider important when choosing treatment for prostate cancer, and to assess why men reject watchful waiting as a treatment option.
PARTICIPANTS: One hundred two consecutive men with newly diagnosed localized prostate cancer identified from hospital and community-based urology practice groups.
MEASUREMENTS: Patients were asked open-ended questions about likes and dislikes of all treatments considered, how they chose their treatment, and reasons for rejecting watchful waiting. The interviews were conducted in person, after the men had made a treatment decision but before they received the treatment.
MAIN RESULTS: The most common reasons for liking a treatment were removal of tumor for radical prostatectomy (RP) (n=15), evidence for external beam radiation (EBRT) (n=6), and short duration of therapy for brachytherapy (seeds) (n=25). The most frequently cited dislikes were high risk of incontinence for RP (n=46), long duration of therapy for EBRT (n=29), and lack of evidence for seeds (n=16). Only 12 men chose watchful waiting. Fear of future consequences, cited by 64% (n=90) of men, was the most common reason to reject watchful waiting.
CONCLUSION: In discussing treatment options for localized prostate cancer, clinicians, including primary care providers, should recognize that patients’ decisions are often based on specific beliefs regarding each therapy’s intrinsic characteristics, supporting evidence, or pattern of complications. Even if patients do not recall a physician recommendation against watchful waiting, this option may not be chosen because of fear of future consequences.
- Landis, SH, Murray, T, Bolden, S, Wingo, PA (1995) Cancer statistics, 1998. CA Cancer J Clin 48: pp. 6-29
- Woolf, SH (1995) Screening for prostate cancer with prostate-specific antigen. N Engl J Med 333: pp. 1401-5 CrossRef
- Dorr, VJ, Williamson, SK, Stephens, RL (1993) An evaluation of prostatespecific antigen as a screening test for prostate cancer. Arch Intern Med 153: pp. 2529-37 CrossRef
- Perkins, T (1994) Concern grows over prostate cancer treatment options. JNCI 86: pp. 987-8
- Menon, M, Parulker, BG, Baker, S (1995) Should we treat localized prostate cancer. An opinion. Urology 46: pp. 607-15 CrossRef
- Walsh, PC The natural history of localized prostate cancer: a guide to therapy. In: Walsh, PC, Retik, AB, Vaughn, ED, Wen, AJ eds. (1998) Campbell’s Urology. W.B. Saunders, Philadelphia, PA, pp. 2539-44
- Hahn, DL, Roberts, RG (1993) Screening for asymptomatic prostate cancer: truth in advertising. J Fam Pract 37: pp. 432-6
- Litwin, MS, Hays, RD, Fink, A. (1995) Quality-of-life outcomes in men treated for localized prostate cancer. JAMA 273: pp. 129-35 CrossRef
- Andriole, GL, Smith, DS, Rao, G, Goodnough, L, Catalona, WJ (1994) Early complications of contemporary anatomical radical retropubic prostatectomy. Urology 152: pp. 1858-60
- Fowler, FJ, Roman, A, Barry, MJ, Wasson, J, Lu-Yao, G, Wennberg, JE (1993) Patient-reported complications and follow-up treatment after radical prostatectomy. The national Medicare experience: 1988–1990. Urology 42: pp. 622-9 CrossRef
- Garnick, MB, Fair, WR (1996) Prostate cancer: emerging concepts. Part I. Ann Intern Med 125: pp. 118-25
- Fleming, C, Wasson, JH, Albertsen, PC, Barry, MJ, Wennberg, JE (1993) A decision analysis of alternative treatment strategies for clinically localized prostate cancer. JAMA 269: pp. 2650-8 CrossRef
- Schroder, FH (1995) Screening, early detection, and treatment of prostate cancer: a European view. Urology 46: pp. 62-70 CrossRef
- Graverson, PH, Nielsen, KT, Gasser, TC, Corle, DK, Madsen, PO (1990) Radical prostatectomy versus expectant primary treatment in stages I and II prostatic cancer. A fifteen year follow-up. Urology 36: pp. 493-8 CrossRef
- Middleton, RG, Thompson, IM, Austenfeld, MS (1995) Prostate Cancer Clinical Guidelines Panel Summary report on the management of clinically localized prostate cancer. The American Urological Association. J Urol 154: pp. 2144-8 CrossRef
- Saltus R. For prostate cancer there’s no magic bullet. Boston Globe. January 12, 1998:C1.
- Schapira, MM, Nattinger, AB, Katz, DA, Lawrence, W (1997) Information seeking and satisfaction with treatment decision in patients with clinically localized prostate cancer. Med Decis Making 17: pp. 544-544
- Fowler, FJ, Bin, L, Collins, MM (1998) Prostate cancer screening and beliefs about treatment efficacy: a national survey of primary care physicians and urologists. Am J Med 104: pp. 526-32 CrossRef
- Feinstein, AR (1987) Clinimetrics. Yale University Press, New Haven
- Charlson, ME, Pompei, P, Ales, KL, MacKenzie, CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40: pp. 373-83 CrossRef
- D’Amico, AV, Coleman, CN (1996) Role of interstitial radiotherapy in the management of clinically organ-confined prostate cancer: the jury is still out. J Clin Oncol 14: pp. 304-15
- Slovic, P (1987) Perception of risk. Science 236: pp. 280-5 CrossRef
- Kattan, MW, Cowen, ME, Miles, BJ (1997) A decision analysis for treatment of clinically localized prostate cancer. J Gen Intern Med 12: pp. 299-305 CrossRef
- Johansson, JE (1994) Watchful waiting for early stage prostate cancer. Urology 43: pp. 138-42 CrossRef
- Sandhu, SS, Kaisary, AV (1996) Localised carcinoma of the prostate: a paradigm of uncertainty. Postgrad Med J 73: pp. 691-6
- Chodak, GW (1994) The role of watchful waiting in the management of localized prostate cancer. J Urol 152: pp. 1766-8
- Steinberg, GD, Bales, GT, Brendler, CB (1998) An analysis of watchful waiting for clinically localized prostate cancer. J Urol 159: pp. 1431-6 CrossRef
- Treatment decisions for localized prostate cancer
Journal of General Internal Medicine
Volume 15, Issue 10 , pp 694-701
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- localized prostate cancer
- decision making
- Industry Sectors
- Author Affiliations
- 1. the Division of General Medicine, National Naval Medical Center, Bethesda, Md
- 3. Clinical Epidemiology Unit, West Haven Veterans Affairs Medical Center, West Haven, Conn
- 4. Department of Medicine and the Robert Wood Johnson Clinical Scholars Program, Yale University School of Medicine, New Haven, Conn